Free Trial

Niagen Bioscience (NAGE) Competitors

Niagen Bioscience logo
$14.13 +0.49 (+3.59%)
As of 06/24/2025 04:00 PM Eastern

NAGE vs. ADMA, PCVX, ZLAB, PTCT, RYTM, CYTK, ACAD, KRYS, MRUS, and RNA

Should you be buying Niagen Bioscience stock or one of its competitors? The main competitors of Niagen Bioscience include ADMA Biologics (ADMA), Vaxcyte (PCVX), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Merus (MRUS), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.

Niagen Bioscience vs. Its Competitors

Niagen Bioscience (NASDAQ:NAGE) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 9.4% of Niagen Bioscience shares are held by company insiders. Comparatively, 3.7% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ADMA Biologics has a net margin of 45.01% compared to Niagen Bioscience's net margin of 13.07%. ADMA Biologics' return on equity of 47.16% beat Niagen Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Niagen Bioscience13.07% 19.06% 12.20%
ADMA Biologics 45.01%47.16%30.51%

Niagen Bioscience has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

ADMA Biologics received 409 more outperform votes than Niagen Bioscience when rated by MarketBeat users. However, 100.00% of users gave Niagen Bioscience an outperform vote while only 72.05% of users gave ADMA Biologics an outperform vote.

CompanyUnderperformOutperform
Niagen BioscienceOutperform Votes
6
100.00%
Underperform Votes
No Votes
ADMA BiologicsOutperform Votes
415
72.05%
Underperform Votes
161
27.95%

Niagen Bioscience currently has a consensus target price of $19.50, suggesting a potential upside of 38.00%. ADMA Biologics has a consensus target price of $27.67, suggesting a potential upside of 55.00%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Niagen Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Niagen Bioscience
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
ADMA Biologics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

ADMA Biologics has higher revenue and earnings than Niagen Bioscience. ADMA Biologics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Niagen Bioscience$99.60M11.17$8.55M$0.1783.12
ADMA Biologics$426.45M9.99$197.67M$0.8521.00

In the previous week, Niagen Bioscience had 1 more articles in the media than ADMA Biologics. MarketBeat recorded 8 mentions for Niagen Bioscience and 7 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.56 beat Niagen Bioscience's score of 0.12 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Niagen Bioscience
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
ADMA Biologics
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

ADMA Biologics beats Niagen Bioscience on 12 of the 18 factors compared between the two stocks.

Get Niagen Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAGE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAGE vs. The Competition

MetricNiagen BioscienceMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.07B$2.81B$5.19B$8.61B
Dividend YieldN/A2.72%5.38%4.23%
P/E Ratio83.1221.3025.7419.50
Price / Sales11.17294.02398.88117.29
Price / Cash230.6042.0435.5255.95
Price / Book23.557.437.975.60
Net Income$8.55M-$55.10M$3.15B$248.44M
7 Day Performance2.54%1.16%0.83%1.15%
1 Month Performance43.02%8.41%5.23%4.89%
1 Year PerformanceN/A-0.38%37.55%17.53%

Niagen Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAGE
Niagen Bioscience
1.3898 of 5 stars
$14.13
+3.6%
$19.50
+38.0%
N/A$1.07B$99.60M83.12120Analyst Upgrade
ADMA
ADMA Biologics
3.5513 of 5 stars
$18.14
-4.0%
$24.25
+33.7%
+62.1%$4.33B$426.45M21.34530
PCVX
Vaxcyte
3.0289 of 5 stars
$33.42
-0.7%
$136.50
+308.5%
-55.0%$4.31BN/A-8.37160Positive News
Gap Up
ZLAB
Zai Lab
2.2893 of 5 stars
$36.91
-0.8%
$47.37
+28.3%
+100.4%$4.07B$398.99M-14.821,869Insider Trade
Analyst Revision
PTCT
PTC Therapeutics
4.6628 of 5 stars
$50.40
-0.9%
$65.00
+29.0%
+38.7%$3.99B$806.78M7.741,410
RYTM
Rhythm Pharmaceuticals
4.1359 of 5 stars
$61.42
-0.9%
$76.62
+24.7%
+49.7%$3.91B$130.13M-21.86140Positive News
CYTK
Cytokinetics
4.2389 of 5 stars
$32.71
+0.5%
$70.92
+116.9%
-38.0%$3.91B$18.47M-6.18250
ACAD
ACADIA Pharmaceuticals
3.8368 of 5 stars
$22.93
+0.5%
$26.79
+16.8%
+41.1%$3.84B$957.80M16.73510Analyst Forecast
KRYS
Krystal Biotech
4.575 of 5 stars
$132.01
+1.5%
$211.13
+59.9%
-19.4%$3.81B$290.52M31.73210News Coverage
Positive News
Analyst Forecast
MRUS
Merus
3.3918 of 5 stars
$52.60
-0.9%
$84.64
+60.9%
-4.9%$3.64B$36.13M-12.8937Insider Trade
RNA
Avidity Biosciences
2.3661 of 5 stars
$29.32
-0.1%
$66.56
+127.0%
-24.7%$3.53B$10.90M-9.77190Analyst Forecast
Gap Up

Related Companies and Tools


This page (NASDAQ:NAGE) was last updated on 6/25/2025 by MarketBeat.com Staff
From Our Partners